VKTX vs VRDN: stock comparison and AI forecast
Viking Therapeutics, Inc. (VKTX) and Viridian Therapeutics, Inc.\De (VRDN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
VKTX Viking Therapeutics, Inc.
- Price
- $25.79 -18.3% · 6M
- Market Cap
- $3.29B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
VRDN Viridian Therapeutics, Inc.\De
- Price
- $28.49 +67.6% · 6M
- Market Cap
- $3.23B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- VKTX and VRDN have similar market capitalizations ($3.29B and $3.23B).
- Over the last six months VRDN returned +67.6% and VKTX -18.3%.
- VRDN carries 0.77 times debt per unit of equity, against 0.66 times for VKTX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | VKTX | VRDN |
|---|---|---|
| Market Cap | $3.29B | $3.23B |
| P/B Ratio | 5.59x | 5.56x |
| EPS | $-6.40 | – |
| Book Value/Share | $4.62 | $5.13 |
| Revenue/Share | $0.00 | $0.23 |
| FCF/Share | – | $-3.03 |
Profitability & Margins
| Metric | VKTX | VRDN |
|---|---|---|
| ROE | -106.6% | -78.1% |
| ROA | -64.2% | -44.1% |
| ROIC | -76.9% | -48.9% |
| Operating Margin | – | -1800.4% |
| Net Margin | – | -1742.5% |
| EBT Margin | – | -1800.4% |
Financial Health
| Metric | VKTX | VRDN |
|---|---|---|
| Current Ratio | 7.27x | 14.46x |
| Quick Ratio | – | 14.46x |
| D/E Ratio | 0.66x | 0.77x |
| Financial Leverage | 1.66x | 1.77x |
| Interest Coverage | 86.9x | -46.5x |
| Working Capital | $839M | $943M |
Cash Flow
| Metric | VKTX | VRDN |
|---|---|---|
| Operating Cash Flow | -$463M | -$342M |
| Free Cash Flow | – | -$343M |
| Capital Spending | – | -$2M |
| FCF/Sales | – | -1319.4% |
| CapEx/Sales | – | 7.5% |
Operational Efficiency
| Metric | VKTX | VRDN |
|---|---|---|
| Asset Turnover | 0.00x | 0.03x |
| Receivables Turnover | – | 0.9x |
| Fixed Assets Turnover | – | 8.8x |
| Days Sales Outstanding | – | 418 days |
Income Statement
| Metric | VKTX | VRDN |
|---|---|---|
| Total Revenue | $0.00M | $26M |
| Operating Income | -$649M | -$469M |
| Net Income | -$627M | -$454M |
| R&D Expense | $586M | $309M |
| SG&A Expense | – | $247M |
Dividend & Shareholder Information
| Metric | VKTX | VRDN |
|---|---|---|
| Shares Outstanding | 128M | 113M |
VKTX vs VRDN: stock comparison and AI forecast
Which is bigger, VKTX or VRDN?
VKTX and VRDN have similar market capitalizations ($3.29B and $3.23B).
Which stock performed better over the last six months, VKTX or VRDN?
Over the last six months VRDN returned +67.6% and VKTX -18.3%.
Which one does Intratio's AI model rank higher, VKTX or VRDN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.